Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Organon & Co (NYSE: OGN) closed the day trading at $6.75 up 2.74% from the previous closing price of $6.57. In other words, the price has increased by $2.74 from its previous closing price. On the day, 8.05 million shares were traded. OGN stock price reached its highest trading level at $6.925 during the session, while it also had its lowest trading level at $6.55.
Ratios:
For a better understanding of OGN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 12.14 whereas as Long-Term Debt/Eq ratio is at 11.98.
JP Morgan Downgraded its Neutral to Underweight on September 06, 2024, whereas the target price for the stock was revised from $18 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 14 ’25 when COX CARRIE SMITH bought 12,469 shares for $8.07 per share. The transaction valued at 100,591 led to the insider holds 12,469 shares of the business.
Falcione Aaron bought 5,500 shares of OGN for $48,235 on May 07 ’25. The Chief Human Resources Officer now owns 62,974 shares after completing the transaction at $8.77 per share. On May 06 ’25, another insider, Weaver Kirke, who serves as the Gen. Counsel & Corp. Secy. of the company, bought 8,045 shares for $9.21 each. As a result, the insider paid 74,054 and bolstered with 52,489 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OGN now has a Market Capitalization of 1754767744 and an Enterprise Value of 10051767296. As of this moment, Organon’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.51, and their Forward P/E ratio for the next fiscal year is 1.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.28 while its Price-to-Book (P/B) ratio in mrq is 2.39. Its current Enterprise Value per Revenue stands at 1.6 whereas that against EBITDA is 5.994.
Stock Price History:
The Beta on a monthly basis for OGN is 0.56, which has changed by -0.60106385 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, OGN has reached a high of $19.05, while it has fallen to a 52-week low of $6.18. The 50-Day Moving Average of the stock is -30.09%, while the 200-Day Moving Average is calculated to be -40.26%.
Shares Statistics:
Over the past 3-months, OGN traded about 4.96M shares per day on average, while over the past 10 days, OGN traded about 10245280 shares per day. A total of 259.96M shares are outstanding, with a floating share count of 259.02M. Insiders hold about 0.36% of the company’s shares, while institutions hold 84.31% stake in the company. Shares short for OGN as of 1760486400 were 12151104 with a Short Ratio of 2.45, compared to 1757894400 on 13694797. Therefore, it implies a Short% of Shares Outstanding of 12151104 and a Short% of Float of 6.23.
Earnings Estimates
A detailed examination of Organon & Co (OGN) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.9, with high estimates of $0.98 and low estimates of $0.73.
Analysts are recommending an EPS of between $3.91 and $3.69 for the fiscal current year, implying an average EPS of $3.85. EPS for the following year is $4.04, with 6.0 analysts recommending between $4.26 and $3.7.
Revenue Estimates
4 analysts predict $1.58B in revenue for . The current quarter. It ranges from a high estimate of $1.59B to a low estimate of $1.56B. As of . The current estimate, Organon & Co’s year-ago sales were $1.58BFor the next quarter, 4 analysts are estimating revenue of $1.61B. There is a high estimate of $1.65B for the next quarter, whereas the lowest estimate is $1.57B.
A total of 6 analysts have provided revenue estimates for OGN’s current fiscal year. The highest revenue estimate was $6.33B, while the lowest revenue estimate was $6.26B, resulting in an average revenue estimate of $6.29B. In the same quarter a year ago, actual revenue was $6.4BBased on 6 analysts’ estimates, the company’s revenue will be $6.33B in the next fiscal year. The high estimate is $6.39B and the low estimate is $6.19B.
